Why Zevra Therapeutics Stock Zoomed 21% Higher Today [Yahoo! Finance]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Yahoo! Finance
Zevra Therapeutics (NASDAQ: ZVRA) was one of the healthier companies on the stock exchange on Tuesday. Investors eagerly piled into its shares following the commercial-stage biotech 's latest earnings release, leaving Zevra with a slightly over 21% gain that day. Two convincing beats Zevra's final set of 2025 earnings was released just after market close Monday, revealing that the company's net revenue was slightly over $34 million in the fourth quarter. That was 44% higher than the same period of 2024. Better, the company flipped to a net profit under generally accepted accounting principles (GAAP) of $12.2 million ($0.19) per share, from the year-ago loss of $35.7 million. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. This meant a crushing double beat for Zevra, as analysts
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Ties NPC Testing Push To Valuation Gap And New CFO [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics (ZVRA) is now covered by BTIG Research. They set a "buy" rating and a $23.00 price target on the stock.MarketBeat
ZVRA
Earnings
- 3/9/26 - Beat
ZVRA
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 3
- 3/16/26 - Form 144
- ZVRA's page on the SEC website